SK902004A3 - Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze - Google Patents

Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze Download PDF

Info

Publication number
SK902004A3
SK902004A3 SK90-2004A SK902004A SK902004A3 SK 902004 A3 SK902004 A3 SK 902004A3 SK 902004 A SK902004 A SK 902004A SK 902004 A3 SK902004 A3 SK 902004A3
Authority
SK
Slovakia
Prior art keywords
crystal
malic acid
pyrrole
diethylamino
fluoro
Prior art date
Application number
SK90-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Hawley
Thomas J. Fleck
Stephen P. Prescott
Mark T. Maloney
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK902004(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of SK902004A3 publication Critical patent/SK902004A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
SK90-2004A 2001-08-15 2002-08-13 Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze SK902004A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (1)

Publication Number Publication Date
SK902004A3 true SK902004A3 (sk) 2005-03-04

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
SK90-2004A SK902004A3 (sk) 2001-08-15 2002-08-13 Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze

Country Status (42)

Country Link
US (2) US20030069298A1 (https=)
EP (3) EP2332934B1 (https=)
JP (1) JP4159988B2 (https=)
KR (1) KR100639281B1 (https=)
CN (2) CN100364991C (https=)
AP (1) AP1660A (https=)
AR (1) AR036261A1 (https=)
AU (1) AU2002324684B2 (https=)
BG (1) BG108553A (https=)
BR (1) BR0211612A (https=)
CA (1) CA2455050C (https=)
CO (1) CO5550431A2 (https=)
CU (1) CU23713B7 (https=)
CY (1) CY1121552T1 (https=)
CZ (1) CZ2004196A3 (https=)
DK (2) DK3168218T3 (https=)
EA (1) EA006445B9 (https=)
EC (1) ECSP044975A (https=)
ES (3) ES2705063T3 (https=)
GE (1) GEP20063777B (https=)
HR (1) HRP20040112B1 (https=)
HU (1) HU229206B1 (https=)
IL (1) IL160097A0 (https=)
IS (1) IS7147A (https=)
MA (1) MA27058A1 (https=)
ME (1) ME00414B (https=)
MX (1) MXPA04001452A (https=)
MY (1) MY139383A (https=)
NO (1) NO326508B1 (https=)
NZ (1) NZ531232A (https=)
OA (1) OA12650A (https=)
PL (1) PL216524B1 (https=)
PT (2) PT3168218T (https=)
RS (1) RS53251B (https=)
SI (2) SI3168218T1 (https=)
SK (1) SK902004A3 (https=)
TN (1) TNSN04028A1 (https=)
TR (1) TR201900509T4 (https=)
TW (1) TWI269796B (https=)
UA (1) UA76483C2 (https=)
WO (1) WO2003016305A1 (https=)
ZA (1) ZA200400706B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
EP1670785B1 (en) * 2003-10-02 2010-07-07 Pharmacia & Upjohn Company LLC Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
PT1773811E (pt) * 2004-07-22 2010-10-19 Lilly Co Eli Um hidrato cristalino variável de sal de hemissuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2- hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinicarbox amida
RU2007141654A (ru) * 2005-05-12 2009-05-20 Пфайзер Инк. (US) Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
NZ566033A (en) 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009104021A2 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
KR20100135910A (ko) 2008-04-16 2010-12-27 낫코 파마 리미티드 수니티닙 염기의 신규한 다형 형태
EP2292613B1 (en) * 2008-05-23 2015-09-30 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
WO2009150523A1 (en) * 2008-06-13 2009-12-17 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CN102203085A (zh) * 2008-07-10 2011-09-28 基因里克斯(英国)有限公司 用于制备苹果酸舒尼替尼晶体形式的新方法
EP2342195B1 (en) * 2008-07-24 2014-09-10 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CA2735084A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) * 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
AU2011222470A1 (en) 2010-03-04 2012-09-27 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en) 2010-03-18 2016-06-30 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
JP2016535989A (ja) 2013-11-01 2016-11-24 ファイザー・インク 前立腺関連抗原を発現させるためのベクター
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
KR20220003512A (ko) * 2019-04-18 2022-01-10 미터 헬스, 인코포레이티드 호흡성 부정맥을 치료하기 위한 방법 및 조성물
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170330B1 (pl) 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
RO114326B1 (ro) 1992-06-05 1999-03-30 Merck Sharp & Dohme Limited Ho Sarea sulfat a unui triazol substituit, procedeu de obtinere a acesteia, compozitie farmaceutica si procedeu de obtinere a acesteia
US5721359A (en) 1993-03-12 1998-02-24 Pharmacia & Upjohn Company Crystalline ceftiofur free acid
US5665878A (en) * 1994-08-31 1997-09-09 Eli Lilly And Company Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
TR199900298T2 (xx) 1996-08-14 1999-05-21 G.D. Searle &Co. 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
CN1104378C (zh) * 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
CN1275126A (zh) 1998-06-19 2000-11-29 帝人株式会社 2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
PT1233943E (pt) * 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
WO2009104021A2 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
HK1066542A1 (en) 2005-03-24
OA12650A (en) 2006-06-19
HRP20040112A2 (en) 2004-06-30
IL160097A0 (en) 2004-06-20
EP1419151A1 (en) 2004-05-19
TWI269796B (en) 2007-01-01
ECSP044975A (es) 2004-03-23
BG108553A (bg) 2005-04-30
US20030069298A1 (en) 2003-04-10
MY139383A (en) 2009-09-30
SI1419151T1 (sl) 2014-04-30
EA006445B9 (ru) 2017-02-28
EP2332934B1 (en) 2017-03-01
AP1660A (en) 2006-09-09
HRP20040112B1 (en) 2012-03-31
EP3168218A1 (en) 2017-05-17
NO20041054L (no) 2004-03-12
PL216524B1 (pl) 2014-04-30
RS53251B (sr) 2014-08-29
JP4159988B2 (ja) 2008-10-01
CU20040029A7 (es) 2008-03-14
PT3168218T (pt) 2019-01-11
HK1088008A1 (zh) 2006-10-27
JP2005503386A (ja) 2005-02-03
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
MXPA04001452A (es) 2004-05-20
WO2003016305A1 (en) 2003-02-27
GEP20063777B (en) 2006-03-27
IS7147A (is) 2004-02-10
TR201900509T4 (tr) 2019-02-21
EA006445B1 (ru) 2005-12-29
CN1789264A (zh) 2006-06-21
ES2705063T3 (es) 2019-03-21
EA200400183A1 (ru) 2004-08-26
PL368317A1 (en) 2005-03-21
CA2455050C (en) 2007-02-20
CN1543462A (zh) 2004-11-03
CN100439360C (zh) 2008-12-03
US7435832B2 (en) 2008-10-14
NZ531232A (en) 2004-11-26
CZ2004196A3 (cs) 2005-01-12
ES2623094T3 (es) 2017-07-10
EP3168218B1 (en) 2018-11-14
TNSN04028A1 (fr) 2006-06-01
KR100639281B1 (ko) 2006-10-31
AP2004002976A0 (en) 2004-03-31
HUP0700036A2 (en) 2008-10-28
EP1419151B1 (en) 2014-02-26
KR20040030074A (ko) 2004-04-08
PT1419151E (pt) 2014-03-27
ES2453164T3 (es) 2014-04-04
NO326508B1 (no) 2008-12-15
CY1121552T1 (el) 2020-05-29
MA27058A1 (fr) 2004-12-20
CA2455050A1 (en) 2003-02-27
EP2332934A1 (en) 2011-06-15
SI3168218T1 (sl) 2019-05-31
ME00414B (me) 2011-10-10
ZA200400706B (en) 2005-05-25
DK1419151T3 (da) 2014-03-31
AR036261A1 (es) 2004-08-25
UA76483C2 (en) 2006-08-15
CU23713B7 (es) 2011-10-05
RS10304A (sr) 2007-02-05
CO5550431A2 (es) 2005-08-31
US20070191458A1 (en) 2007-08-16
DK3168218T3 (en) 2019-01-14
AU2002324684B2 (en) 2006-10-05
BR0211612A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
SK902004A3 (sk) Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze
AU2002324684A1 (en) Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
RU2434851C1 (ru) Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
WO2007146375A2 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
HK1088008B (en) 2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
HK1066542B (en) Crystals including a malic acid salt of n-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxo-3h-indole-3-ylidene) methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
SK281782B6 (sk) Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
HK1115382A (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate

Legal Events

Date Code Title Description
FD9A Suspended procedure due to non-payment of fee